Perrigo Company

ALLEGAN, Mich., May 7, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its third quarter ended March 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the ... read more

ALLEGAN, Mich., March 18, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has begun shipments of Guaifenesin 600mg Extended-Release tablets in a launch to its retail and wholesale customers. This major new product is the first product that is generically equivalent to Mucinex® ... read more

ALLEGAN, Mich., March 11, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Barclays Global Healthcare Conference on Wednesday, March 13, at 3:45 PM (EDT) in Miami, FL. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) From its beginnings as a ... read more

ALLEGAN, Mich., Feb. 25, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the RBC Global Healthcare Conference on Wednesday, February 27, at 10:30 AM (EST) in New York City, NY. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) From its beginnings ... read more

ALLEGAN, Mich., Feb. 19, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone gel 1.62% and that it has notified AbbVie Inc., the owner of the Reference Listed ... read more

ALLEGAN, Mich., Feb. 12, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer Judy Brown will present at the Leerink Swann Global Healthcare Conference on Thursday, February 14, at 8:30 AM (EST) in New York City, NY. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ... read more

ALLEGAN, Mich., Feb. 11, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive merger agreement and has completed the acquisition of Leeds, U.K.-based Rosemont Pharmaceuticals Ltd. ("Rosemont") for approximately £180 million or $283 million in cash. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO) Founded in 1967, Rosemont is a specialty ... read more

ALLEGAN, Mich., Feb. 1, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has launched clobetasol emulsion propionate foam, 0.05%, the generic equivalent of Olux® -E Foam, 0.05%. Perrigo will commence shipment of the product immediately. As Perrigo was the first generic filer against ... read more

ALLEGAN, Mich., Feb. 1, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire Yardley, PA based Velcera, Inc. for $160 million in cash. The acquisition is expected to close during calendar year 2013 ... read more

ALLEGAN, Mich., Feb. 1, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its second quarter ended December 29, 2012. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) Perrigo's Chairman and CEO Joseph C. Papa commented, "The team delivered on another high-quality quarter with all-time record ... read more

ALLEGAN, Mich., Jan. 31, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.09 per share, payable on March 19, 2013 to shareholders of record on March 1, 2013. (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ) From its beginnings as a packager of ... read more

ALLEGAN, Mich., Jan. 18, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE:) today announced that it will release financial results for its second quarter fiscal year 2013 on Friday, February 1, 2013 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. ... read more

ALLEGAN, Mich., Jan. 15, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq® Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, Inc. ("Cobrek"), which was recently acquired ... read more

ALLEGAN, Mich., Jan. 7, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has made initial shipments distributing Cumberland Pharmaceuticals Inc.'s ("Cumberland") Authorized Generic form of Acetadote® (acetylcysteine) injection. The Authorized Generic is free of EDTA and any other chelating, stabilization or preservative agents. (Logo: ... read more

ALLEGAN, Mich., Jan. 2, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the J.P. Morgan 31(st) Annual Healthcare Conference on Monday, January 7, 2013 at the Westin St. Francis Hotel in San Francisco, ... read more

ALLEGAN, Mich., Dec. 28, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately-held, Chicago, Illinois-based drug development company, for approximately $45 ... read more

ALLEGAN, Mich., Dec. 4, 2012 /PRNewswire/ -- The Perrigo Company (Nasdaq: PRGO;TASE) today announced the appointment of Douglas Boothe as Executive Vice President and General Manager, Perrigo Pharmaceuticals, effective January 2013. Sharon Kochan, who previously held this position, has been managing the business in the interim since ... read more

ALLEGAN, Mich., Nov. 28, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev® (acetaminophen) injection brought by Cadence Pharmaceuticals, Inc. ("Cadence"). Under the terms of the settlement, Perrigo can launch a generic version of ... read more

ALLEGAN, Mich., Nov. 27, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, the generic equivalent of Luxiq® Foam. ... read more

ALLEGAN, MI -- (Marketwire) -- 04/22/09 -- Perrigo Company (NASDAQ: PRGO) (TASE: PRGO) today announced that it will release financial results for its third quarter fiscal year 2009 on Thursday, May 7, 2009 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph ... read more